Filing Details

Accession Number:
0001104659-24-129864
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-12-18 21:00:13
Reporting Period:
2024-12-16
Accepted Time:
2024-12-18 21:00:13
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1737953 Replimune Group Inc. REPL Biological Products, (No Disgnostic Substances) (2836) 822082553
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1860609 Sushil Patel C/O Replimune Group, Inc.
500 Unicorn Park Drive, Suite 303
Woburn MA 01801
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-12-16 10,000 $12.42 202,014 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on April 3, 2024, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
  2. The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.20 to $12.62. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  3. Following the sales reported on this Form 4, the reporting person continues to beneficially own 202,014 shares of the Issuer's common stock, including restricted stock units. The reporting person also holds options to acquire an aggregate of 513,750 shares of the Issuer's common stock, 189,478 of which are exercisable as of the date hereof.